An improved radiosynthesis of [(18)F]FAraG, a PET radiotracer for imaging T‐cell activation

In this concise practitioner protocol, the radiochemical synthesis of 2′‐deoxy‐2′‐[(18)F]fluoro‐9‐β‐d‐arabinofuranosylguanine ([(18)F]FAraG) suitable for human positron emission tomography (PET) studies is described and the results from validation productions are presented. The high specific activity (sometimes referred to as molar activity) radiotracer product is prepared as a sterile, apyrogenic solution that conforms to current Good Manufacturing Practice (cGMP) requirements established by the U.S. Food and Drug Administration.